ITGAX and neoplasm: The findings showed that the number of mature CD86+ CD11c+ DCs increased in the draining lymph nodes from 6.05% for blank mice and 10.8% for untreated tumor-bearing mice to 16.5% for PECT-Cur NPs-treated tumor-bearing mice.